nimodipine
Sign in to saveNimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication.
Research
5,036 papers- Nimodipine improves vocal fold and facial motion recovery after injury: A systematic review and meta-analysis.The Laryngoscope · 2019
- Nimodipine in Clinical Practice: A Pharmacological Update.The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses · 2022
- Nimodipine Pharmacokinetic Variability in Various Patient Populations.Drugs in R&D · 2020
- Nimodipine Reappraised: An Old Drug With a Future.Current neuropharmacology · 2020
- Nimodipine for the treatment of otolaryngic indications.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2018
via PubMed
Article
13 sectionsContents
- Medical use
- Dosage
- Contraindications
- Side effects
- Pharmacokinetics
- Absorption
- Metabolism
- Excretion
- Mechanism of action
- Synthesis
- Stereochemistry
- References
- Further reading
Nimodipine, sold under the brand name Nimotop among others, is a calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication.
It was patented in 1971 and approved for medical use in the United States in 1988. It was approved for medical use in Germany in 1985.